Media Coverage

Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing. Shares of the ​New Jersey-based company were up about 4% in early trading.

A blood test based from a South Baltimore lab is making treatment clearer for cancer patients. HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that conventional methods may miss. While it's been in development for many, many years, the test was made clinically available for oncologists and pharmaceutical partners in late 2024.

In this exclusive interview, Quest Diagnostics’ Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann.

Per- and polyfluorinated alkyl substances, or PFAS, are known by many as “forever chemicals” due to the way they can accumulate and linger in the environment and body. These chemicals are widely used in thousands of industrial and consumer products and may enter the body through contaminated food and water. Research by Quest Diagnostics outlined similar results: men that were tested using the company’s PFAS blood test had higher PFAS concentrations in their blood than women who were tested.

Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting in April, providers with a Quest account will be able to order HelioLiver, a test designed for early detection of hepatocellular carcinoma, through Quest’s network, according to a March 18 news release shared with Becker’s.

Guardant Health’s Shield blood-based colorectal cancer screening test is now available for physician ordering through Quest Diagnostics’ nationwide network, the companies announced March 10, giving clinicians a new avenue to access the only blood test with full Food and Drug Administration approval as a primary colorectal cancer (CRC) screening option for average-risk adults aged 45 and older.

Several large healthcare organizations have announced they have signed on to Google Cloud for Gemini-powered AI agents for patient engagement, improved workflows, revenue cycle capabilities and easier-to-read lab results. At HIMSS26, Google Cloud will show how agentic AI can lead healthcare organizations from siloed data entry to automated results. Quest Diagnostics, which offers diagnostic information services, has announced Quest AI Companion, a new AI-powered chat feature that helps individuals understand Quest laboratory test results. Through the app and portal MyQuest, individuals can ask questions about their test results and receive explanations in a HIPAA-compliant solution.

Quest Diagnostics is launching a chatbot tailored for laboratory test results as it seeks to allow patients the ability to come to terms with their findings and perform deeper dives on their own health. The Quest AI Companion can probe data from patients’ labs for up to five years in order “to help explain results and uncover potential health risks,” according to a March 2 statement.

Quest Diagnostics, a leading provider of diagnostic information services with headquarters in Secaucus, announced that Benjamin Beauvalot has joined the company as senior vice president, chief strategy and M&A officer. “Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class health care organizations,” Davis said.

Quest Diagnostics said its Flow Cytometry MRD for Myeloma test detects minimal residual disease (MRD), the small number of cancer cells that can remain in the body after treatment and potentially lead to relapse, “at a fraction of the cost” of other methods. “Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system,” Yuri Fesko, MD, Quest’s senior vice president and chief medical officer, said in a company press release.

In 2020, as many as 5.8 million Americans were living with Alzheimer’s Disease (AD)—a number projected to nearly triple to 14 million people by 2060.1 As changes in the brain can begin years before the first symptoms appear, the science around assessing risk and diagnosing AD and other dementias is complex and continues to evolve with the publication of new research. (By Michael K. Racke, MD)

Quest Diagnostics reported Tuesday a 7 percent year-over-year increase in its Q4 2025 revenue. Revenue for the three months ended Dec. 31, 2025, was $2.81 billion, up from $2.62 billion in the same quarter last year and above the consensus Wall Street estimate of $2.76 billion. Requisition volumes rose 9 percent during the quarter while revenue per requisition fell less than 1 percent. Organic requisition volume rose 8 percent year over year, the Secaucus, New Jersey-based company said.

Forever chemicals. They’re everywhere — from non-stick pans to seafood to cosmetics. 25 Investigates worked with Quest Diagnostics, which offers a PFAS blood panel that screens for nine common forever chemicals for $350. Quest allowed us to film most of my blood test. We went in before the lab opened one January morning to protect patient privacy. Kavanaugh found the test itself to be quick and painless — just one vial of blood. Quest says it began offering the PFAS blood test in 2024. Quest says theirs is the first PFAS blood test available as a consumer-initiated test with physician oversight based on recommendations by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations.

Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine.

As Quest Diagnostics President and CEO Jim Davis noted at the 44th Annual JP Morgan Healthcare Conference last week, the RESULTS Act still needed to go through markup in a House subcommittee, then receive consideration in the Senate, undergo a technical feasibility assessment by the US Centers for Medicare and Medicaid Services, and then receive a score from the Congressional Budget Office. "That's a lot of work to be done in 18 days," he said. Davis added, however, that he is "optimistic that the RESULTS Act will get passed in 2026" and that Congress will pass a temporary delay as long as the RESULTS Act is making progress toward passage.

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health. The lab giants, in separate agreements announced Thursday, Jan. 8, have added Visby Medical’s newly approved, fully at-home PCR test for sexually transmitted infections to their lineup of direct-to-consumer women’s health offerings.

Southfield, Mich.-based Corewell Health and Secaucus, N.J.-based Quest Diagnostics have finalized a lab joint venture and hospital lab management agreement. Quest Diagnostics and Corewell Health’s existing labs will continue to provide services to the joint venture until a 100,000-square-foot centralized lab at the Corewell Health Southfield Center opens in the first quarter of 2027. The new facility will feature advanced diagnostic technologies, including high-throughput molecular testing and automated microbiology.

Quest Diagnostics handles the blood and other biological specimens of one in three Americans every year — and much of the testing, processing and logistics of those samples runs largely unseen through Tampa Bay.

AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026. Cardiometabolic testing is one example, where labs are being asked to look beyond single endpoints. “In 2025, we saw many individuals focus on weight loss as a means of potentially improving their cardiometabolic health,” says Mouris Saghir, PhD, vice president and general manager for cardiometabolic, endocrine, and wellness at Quest Diagnostics.

Lab testing companies including giants Quest Diagnostics and LabCorp are pressing Congress to stop hundreds of millions of dollars of Medicare cuts for diagnostic tests that are due to take effect at the end of January. Their push could add to the health care issues piling up on lawmakers' plates as the calendar flips over. Clinical lab companies say letting the cuts take effect will leave them with less money to spend on creating new diagnostics or technologies to generate quicker results. "Labs play a critical part in trying to keep the nation well — identifying that risk before it ever even happens," said Yuri Fesko, chief medical officer at Quest.

Quest Diagnostics, a cancer treatment laboratory located in Lewisville, was honored by the Lewisville City Council after developing a medical breakthrough that could decrease the risk of diseases returning to treated patients. The laboratory was recognized for its achievement in developing Haystack MRD, a non-invasive, tumor-informed MRD test that searches for tiny tumor fragments in people who have previously or currently have a solid tumor.

In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.

Even though exercise is good for us, working out can sometimes feel stressful: fitting in time for the gym, making sure we have clean workout clothes, monitoring our daily step count, pushing our runs, rides, and reps to be faster, harder, and just, well, more. If this sounds familiar, you’ll be pleased (and surprised!) to know that the latest fitness trend is all about doing less. If this sounds familiar, you’ll be pleased (and surprised!) to know that the latest fitness trend is all about doing less. In fact, it’s not a traditional workout at all—but it does have some legit benefits for physical health and mental wellbeing. “Getting up and moving around is good for your mental health,” says Marc Penn, M.D., Ph.D., FACC, a senior advisor and medical director of cardio-metabolic endocrine at Quest Diagnostics. Low-intensity activity can improve mood. Plus, clutter can add to stress and mental health issues, so if you’re using your Zone Zero time to tidy up, you get a two-for-one.